- Home
- OPRT vs CRGX Comparison
OPRT vs CRGX Comparison
Compare OPRT & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRT
- CRGX
- Stock Information
- Founded
- OPRT 2005
- CRGX 2021
- Country
- OPRT United States
- CRGX United States
- Employees
- OPRT N/A
- CRGX N/A
- Industry
- OPRT Finance: Consumer Services
- CRGX
- Sector
- OPRT Finance
- CRGX
- Exchange
- OPRT Nasdaq
- CRGX Nasdaq
- Market Cap
- OPRT 221.5M
- CRGX 190.0M
- IPO Year
- OPRT 2019
- CRGX 2023
- Fundamental
- Price
- OPRT $6.29
- CRGX $4.28
- Analyst Decision
- OPRT Hold
- CRGX Hold
- Analyst Count
- OPRT 2
- CRGX 7
- Target Price
- OPRT $5.00
- CRGX $4.67
- AVG Volume (30 Days)
- OPRT 382.7K
- CRGX 571.5K
- Earning Date
- OPRT 05-08-2025
- CRGX 05-08-2025
- Dividend Yield
- OPRT N/A
- CRGX N/A
- EPS Growth
- OPRT N/A
- CRGX N/A
- EPS
- OPRT N/A
- CRGX N/A
- Revenue
- OPRT $746,101,000.00
- CRGX N/A
- Revenue This Year
- OPRT $28.62
- CRGX $58.18
- Revenue Next Year
- OPRT $7.92
- CRGX N/A
- P/E Ratio
- OPRT N/A
- CRGX N/A
- Revenue Growth
- OPRT N/A
- CRGX N/A
- 52 Week Low
- OPRT $2.37
- CRGX $3.00
- 52 Week High
- OPRT $9.25
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- OPRT 51.73
- CRGX 55.09
- Support Level
- OPRT $6.11
- CRGX $4.10
- Resistance Level
- OPRT $6.69
- CRGX $4.27
- Average True Range (ATR)
- OPRT 0.39
- CRGX 0.18
- MACD
- OPRT -0.07
- CRGX 0.03
- Stochastic Oscillator
- OPRT 13.24
- CRGX 82.79
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.